PRRT2 and metastatic melanoma: To better understand PKC-θ dynamics during the evolution of therapeutic resistance, we examined the expression of these markers in CTCs isolated throughout the clinical course of a patient with progressive metastatic melanoma who subsequently responded to second-line immunotherapy.